Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Sarcoma 3Thoracic 1Dermatologic 1

Conditions

Lung Neoplasms 29Carcinoma, Non-Small-Cell Lung 23Urinary Bladder Neoplasms 4Melanoma 4Colorectal Neoplasms 3Carcinoma, Renal Cell 3Adenocarcinoma of Lung 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colitis 2Carcinoma, Neuroendocrine 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Radiation Pneumonitis 1Ovarian Neoplasms 1Neoplasm Metastasis 1

Interventions

Radiosurgery 27Radiotherapy 17Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Bevacizumab 13Pemetrexed 10Carboplatin 10pembrolizumab 9Gefitinib 9osimertinib 8icotinib 7Temozolomide 7Nivolumab 6Specimen Handling 5Paclitaxel 5Spermine Synthase 4Mental Status and Dementia Tests 4Ipilimumab 4Drug Therapy 4Cisplatin 4atezolizumab 3alectinib 3aflutinib 3Radiation 3Immunotherapy 3Fluorodeoxyglucose F18 3regorafenib 2paclitaxel-Angiopep-2 conjugate 2motexafin gadolinium 2epothilone B 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Immunoglobulin G × Thoracic × Clear all
NCT02971501 2026-05-29

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

National Cancer Institute (NCI)

Phase 2 Active not recruiting
5 enrolled 9 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡